Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.32 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808531 | 0.83 | REN (0.37) | RENMEN1KMT2AHTR4KCNH2 | |
| SCHEMBL2806950 | 0.81 | REN (0.42) | REN | |
| SCHEMBL2813583 | 0.80 | SLC22A12 (0.39) | RENHTR4KCNH2 | |
| SCHEMBL2833989 | 0.79 | HRH1 (0.37) | RENMEN1KMT2AHTR4KCNH2 | |
| SCHEMBL2810347 | 0.79 | KDM4C (0.40) | RENMEN1KMT2AHTR4KCNH2 | |
| SCHEMBL13132444 | 0.76 | ITK (0.39) | RENMEN1KMT2A | |
| SCHEMBL2840438 | 0.72 | REN (0.37) | RENHTR4KCNH2 | |
| SCHEMBL2806190 | 0.72 | REN (0.45) | RENHTR4KCNH2 | |
| SCHEMBL13131760 | 0.69 | REN (0.61) | REN | |
| SCHEMBL2805458 | 0.66 | HTR4 (0.37) | RENHTR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885MEN1 167/4885KMT2A 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.